



**DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED**

**2348**

			%
	<b>437,202</b>	398,197	9.8
	<b>46,108</b>	48,207	(4.35)
	<b>41,356</b>	45,451	(9.01)
	<b>0.0516</b>	0.0568	(9.15)
	<b>0.015</b>	0.015	
		0.015	
12,064,000	11,804,000		

)

3	<b>437,202</b>	398,197
	<u><b>(339,226)</b></u>	<u>(294,966)</u>
	<b>97,976</b>	103,231
3	<b>1,076</b>	866
	<b>(30,525)</b>	(24,936)
	<b>(18,072)</b>	(18,992)
	<b>(4,347)</b>	(11,443)
	<u>-</u>	<u>(519)</u>
4	<b>46,108</b>	48,207
5	<u><b>(4,712)</b></u>	<u>(2,711)</u>
	<u><b>41,396</b></u>	<u>45,496</u>
	<b>41,356</b>	45,451
	<u><b>40</b></u>	<u>45</u>
	<u><b>41,396</b></u>	<u>45,496</u>
6	<u><b>11,804</b></u>	<u>12,400</u>
7		
	<b>0.0516</b>	0.0568
	<u><b>0.0513</b></u>	<u>0.0567</u>

	<b>232,016</b>	240,741
	<b>13,050</b>	13,204
	<b>1,236</b>	869
	<b>583</b>	-
	<b>16,316</b>	15,362
	<b>477</b>	655
	<u><b>263,678</b></u>	<u>270,831</u>
8	<b>119,279</b>	134,597
9	<b>304,878</b>	288,892
	<b>26,176</b>	16,029
	<b>5,302</b>	3,965
	<b>67,718</b>	44,023
	<u><b>523,353</b></u>	<u>487,506</u>
10	<b>221,700</b>	201,242
	-	25,351
	<b>2,441</b>	1,212
	<b>19,108</b>	17,485
	<u><b>243,249</b></u>	<u>245,290</u>
	<u><b>280,104</b></u>	<u>242,216</u>
	<u><u><b>543,782</b></u></u>	<u><u>513,047</u></u>
	<b>85,298</b>	84,791
	<b>457,721</b>	413,812
	-	13,654
	<u><b>543,019</b></u>	512,257
	<u><b>763</b></u>	790
	<u><u><b>543,782</b></u></u>	<u><u>513,047</u></u>

1

34  
16

34

1  
7

7

1

8

11  
12  
13  
14

19

23

2

3

	<u>437,202</u>	<u>398,197</u>
	478	519
	21	2
	50	20
	286	124
	<u>241</u>	<u>201</u>
	<u>1,076</u>	<u>866</u>

4

	339,226	294,966
	11,566	10,737
*	154	153
**	281	392
	<u>5,845</u>	<u>7,391</u>
	<u>6,126</u>	<u>7,783</u>
	<u>789</u>	<u>633</u>

4 ( )

22,073	21,784
2,067	1,766
706	666
386	509
<u>25,232</u>	<u>24,725</u>

228 496

(526) (86)

108 1,241

\*

\*\*

5

4,398	2,973
136	(262)
178	-
<u>4,712</u>	<u>2,711</u>

6

			<b>13,654</b>	29,127
	0.015		<b>11,804</b>	<u>12,400</u>

Q015	12,064,000	11,804,000
------	------------	------------

7.

41,356,000 (	:	45,451,000 )	
802,090,718 (	:	800,020,552 )	
			41,356,000 (
: 45,451,000 )			806,692,166 (
: 801,307,004 )			

8

	<b>17,739</b>	16,261
	<b>57,458</b>	91,432
	<b>44,082</b>	<u>26,904</u>
	<b>119,279</b>	<u>134,597</u>

90		<b>141,785</b>	125,532
91	180	<b>8,990</b>	11,035
181	270	<b>1,914</b>	1,863
271	360	<b>309</b>	145
		<b>486</b>	334
		<hr/>	<hr/>
		<b>153,484</b>	138,909
		<hr/>	<hr/>
90		<b>129,546</b>	87,035
91	180	<b>21,848</b>	62,948
		<hr/>	<hr/>
		<b>151,394</b>	149,983
		<hr/>	<hr/>
		<b>304,878</b>	288,892
		<hr/> <hr/>	<hr/> <hr/>

90		71,904	74,657
91	180	3,607	629
181	270	876	1,032
271	360	2	98
		<u>266</u>	<u>304</u>

<u>76,655</u>	<u>76,720</u>
---------------	---------------

90		78,041	46,040
91	180	67,004	78,482

<u>145,045</u>	<u>124,522</u>
----------------	----------------

<u><u>221,700</u></u>	<u><u>201,242</u></u>
-----------------------	-----------------------

437,202,000

9.8%

41,356,000

4,095,000

( )

“

“

1.

			437,202,000		( )
					50,230,000
11.5%		88.3%			( )
	45,134,000		20.8%		2%
					49,673,000
7,093,000		5.3%			
					52,944,000
	5.3%			7,096,000	
	22.4%		30,525,000		

2

25 /  
26

3

i) \_\_\_\_\_

( )

130 ( 87 )

1)

2)

ii) \_\_\_\_\_

(European Directorate for the Quality of Medicines, “ EDQM ”)  
(Certification of Suitability to the Monographs of the European Pharmacopoeia,  
“ COS ”)  
60%

iii) \_\_\_\_\_

( U.S. Food and Drug Administration, “ FDA ” )

4

	1,527	25,232,000
24,725,000		

( 37,861,000 ; 39,929,000  
 21,591,000 ; 5,381,000 ( 10,853,000  
 30,191,000 67,718,000  
 44,023,000  
 242,216,000 280,104,000  
 758,337,000 787,031,000  
 3.3% 25,351,000  
 463,400,000 543,400,000  
 43,865,000 118,692,000  
 100% 630,000

( )

3.21

( )

28

26